The immunogenicity and efficacy of pneumococcal vaccines: a systematic review and network meta-analysis of individual participant data

The immunogenicity and efficacy of pneumococcal vaccines: a systematic review and network meta-analysis of individual participant data

Decisions about which vaccines to use in the UK should be made based on good data to make sure we are protected against disease.Pneumococcal disease is a serious illness caused by a bacterial infection that can result in death. Children in the UK receive one type of pneumococcal vaccine to prevent this disease and the vaccine in use has been very successful. Another vaccine is used in other countries, and might be a good option for the UK as it is cheaper. From studies in this area, however, there is very little informationdirectly comparing these two vaccines, so it is difficult to know which is best.We plan to do a large analysis combining all pneumococcal vaccine studies. We will use information from studies published in medical journals, but we will also include data from studies done by the companies that own the vaccines. We have used this sort of company data before and are experienced in analysing it. We aim to show which vaccine produces the highest responses when measured in blood samples in infants and also to show which vaccine protects infants best against infection.Our results will provide the best comparison of pneumococcal vaccines done so far. This will help the UK to decide whether to keep the current vaccine or to change. In turn, this will help to continue to protect the population against disease.

[{ "PostingID": 259, "Title": "GSK-110808", "Description": "Primary vaccination course in children receiving the pneumococcal vaccine GSK 1024850A or Prevenar™ co-administered with Hiberix™" },{ "PostingID": 465, "Title": "GSK-105554", "Description": "Phase IIIa randomized, controlled study to assess the immunogenicity of GlaxoSmithKline (GSK) Biologicals' 10-valent pneumococcal conjugate vaccine, when administered as a 3-dose primary immunization course before 6 months of age" },{ "PostingID": 470, "Title": "GSK-110142", "Description": "Non-inferiority of co-administration of GSK Biologicals'pneumococcal conjugate vaccine GSK1024850A with DTPa-IPV-Hib versus co-administration with DTPa-HBV-IPV/Hib." },{ "PostingID": 2209, "Title": "GSK-105553", "Description": "Assess lot-to-lot consistency of 3 lots (double blind design) of GlaxoSmithKline Biologicals' 10-valent pneumococcal vaccine and evaluate non-inferiority to Prevenar™ (single blind design) when administered as 3-dose primary immunization course before 6 months of age" },{ "PostingID": 2210, "Title": "GSK-107005", "Description": "To assess safety, reactogenicity and immunogenicity of GSK Biologicals' 10-valent pneumococcal conjugate vaccine, when co-administered with DTPa-combined vaccines and MenC or Hib-MenC vaccines during the first 6 months of age." },{ "PostingID": 2211, "Title": "GSK-107007", "Description": "To assess the safety, reactogenicity and immunogenicity of GSK Biologicals' pneumococcal conjugate vaccine compared to Prevenar™, co-administered with DTPw-HBV/Hib & OPV or IPV vaccines as a 3-dose primary immunization course during the first 6 months of age" },{ "PostingID": 4289, "Title": "GSK-103488", "Description": "A randomized, controlled, phase II study to evaluate the safety and immunogenicity of different formulations of GlaxoSmithKline Biologicals' 11-valent pneumococcal conjugate vaccine, when administered intramuscularly as a 3-dose primary immunization (2-3-4 month schedule) before 6 months of age" },{ "PostingID": 19770, "Title": "GSK-113994", "Description": "Safety, reactogenicity & immunogenicity of GSK Biologicals' pneumococcal vaccine 2189242A when co-administered with DTPa-HBV-IPV/Hib vaccine in healthy infants" },{"PostingID":19918,"Title":"GSK-116485","Description":"Immunogenicity and safety study of two formulations of GlaxoSmithKline (GSK) Biologicals' pneumococcal vaccine (2830929A and 2830930A) when administered in healthy infants, Sponsor: GSK"}]